Skip to main content
Premium Trial:

Request an Annual Quote

NCI-Led Breast, Prostate Cancer Genotyping Study to Use ABI s Technology, Protocol

NEW YORK, April 18 (GenomeWeb News) - The National Cancer Institute's Cohort Consortium will use genotyping technology and protocols from Applied Biosystems to study the genetics of breast and prostate cancer, ABI said today.

 

The project, which combines six large prospective cohort studies that include more than 6,000 breast cancer and 8,000 prostate cancer patients, will make use of ABI's TaqMan SNP genotyping assays and 7,900HT real-time PCR systems to identify inherited gene variants that may contribute to the development of the two cancers. The SNP genotyping assays were designed by Applied Biosystems and will be made public to researchers.

 

Preliminary results from a first study by the Cohort Consortium started in 2003, entitled "Breast and Prostate Cancer and Hormone-Related Gene Variants Study," will be presented this week at the AACR meeting in Anaheim, Calif.

 

The NCI Cohort Consortium is a collaboration involving six American and European prospective cohort studies totaling 897,000 participants, three genomic facilities, and six genotyping centers.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.